University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > SFGH PHP Grand Rounds > Lampiris > Slides
HIV Drug Resistance Update 2007
Slide 1.
HIV Drug Resistance Update 2007
Slide 1.
Download slide
Overview of Talk
Slide 2.
Download slide
When to Use Resistance Testing
Slide 3.
Download slide
Case 1: Resistance Testing in Treatment-Naive Patients
Slide 4.
Download slide
Case 1: A Genotype Is Obtained
Slide 5.
Download slide
Prevalence of Drug Resistance in Recently Infected ART-Naive Persons
Slide 6.
Download slide
The SPREAD Study: Transmitted HIV-1 Drug Resistance in Europe
Slide 7.
Download slide
Resistance in Naive Patients: A Global Study
Slide 8.
Download slide
Effects of Selected Nucleoside Mutations on Viral Fitness
Slide 9.
Download slide
Case 2: Salvaging K65R
Slide 10.
Download slide
In This Patient, The Nucs Chosen for His Next Regimen Were Combivir and Tenofovir. Reasonable Choices for Non-Nucleoside Agents in the Patient's Backbone in Next Regimen Include:
Slide 11.
Download slide
Impact of K65R on Treatment Response
Slide 12.
Download slide
Response to Etravirine in Patients with NNRTI and PI Resistance (ITT:NC=F)
Slide 13.
Download slide
Effect of 103N and 181C on Virologic Response to Etravirine (TMC125)
Slide 14.
Download slide
Effect of Baseline Resistance on Response to Etravirine
Slide 15.
Download slide
Case 3: High Level Three Class Resistance in Advanced Disease
Slide 16.
Download slide
Case 3: Antiretroviral History
Slide 17.
Download slide
Case 3: Prior Genotype
Slide 18.
Download slide
Now what?
Slide 19.
Download slide
Considerations for When to Switch HAART
Slide 20.
Download slide
Table 1
Slide 21.
Download slide
Table 2
Slide 22.
Download slide
Next Salvage Regimen?
Slide 	23.
Download slide
Effect of T-20 Plus An Active PI
Slide 24.
Download slide
Clinical Cut-Offs for Genotypic Scores
Slide 25.
Download slide
New r/PI Monogram Phenotype Clinical Cutoffs
Slide 26.
Download slide
Baseline Characteristics of RESIST Patients
Slide 27.
Download slide
RESIST: Week 96 Results - Overall Results
Slide 28.
Download slide
TPV Mutations Associated with Virologic Failure in RESIST Studies
Slide 29.
Download slide
Important Tipranavir Drug Interactions with Newer Agents
Slide 30.
Download slide
Darunavir: POWER 1 and 2 Combined 48 Week Analysis (2006 IAC, #TUAB0104)
Slide 31.
Download slide
Phenotypic and Genotypic Determinants of Darunavir Resistance
Slide 32.
Download slide
Weighing the Mutations Associated with A Diminished Response to Darunavir
Slide 33.
Download slide
Mutations Selected in the Clinical Setting or Associated with Reduced Virological Response
Slide 34.
Download slide
Individual Mutations Associated with Increased Susceptibility to TPV and Darunavir (Vircotype Analysis)
Slide 35.
Download slide
Susceptibility to TPV or DRV after Failure of the Alternative Agent
Slide 36.
Download slide
I50V and Clinical Response in the RESIST Studies
Slide 37.
Download slide
Summary: Tipranavir vs Darunavir I
Slide 38.
Download slide
Summary: Tipranavir vs Darunavir II
Slide 39.
Download slide
Summary: Tipranavir vs Darunavir III
Slide 40.
Download slide
Case 4: MDR HIV: Biding Your Time
Slide 41.
Download slide
3TC Alone vs Treatment Interruption in Patients Failing 3TC-Based Therapy
Slide 42.
Download slide
Change in HIV RNA after 3TC Withdrawal
Slide 43.
Download slide
Risk of Delayed Switch on Stable ART
Slide 44.
Download slide
Studies of Enfuvirtide Resistance and Effects of Discontinuation
Slide 45.
Download slide
Guidelines for Choosing A Partially Suppressive ART Regimen
Slide 46.
Download slide
New ARV Choices: Resisting the Temptation to Use Them Too Soon
Slide 47.
Download slide